Donald Morel: The actual growth Arnie would be still in that kind of – a couple of points less than that. So instead of the 6.6% we had in the packaging systems segment, it would be between one and two points less than that. But remember, the one point to remember Arnie is we have those kinds of situations happen every year in every quarter. We did have as you mentioned a launch of a customer’s new biologic [class] first quarter that stretched into the second. But we have had, not as large, but we have had some of those similar kinds of things happen again this quarter. So to just pull out the launch last year would be somewhat of a misnomer.
Donald Morel: The total sales are – when they are – the total sample is exactly that. It is in – and it is not quite $40 to $50, but it is $30 to $50 per unit.
Donald Morel: It is not in Q1 Arnie. So those numbers – the way you got to look at it is we have made the – actually sent the trial units over to the customer. So we will be recognizing that revenue over a period of time.
Donald Morel: Yes, basically we have got the line in [Robin’s board] up validated and Vetter is running that line dedicated to CZ. We have not had the second unit delivered yet, which will go into the Chicago facility. So if you would remember better, Chicago facility is really aimed at clinical trial volume to support activity here in the United States. So we have got roughly 5 million to 6 million units go into capacity off the line in Germany, and the line in Chicago should come on sometime in the late 2014, early 2015 timeframe.
Donald Morel: Yes, it will be small, but you actually will get the benefit. The Q1 SG&A was driven by a couple of odd things. I mean you had the rise in the stock price and the impact on our variable incentive comp. The Venezuela thing hit us to the tune of about [700] in the other category. And we did have some expenses in advance of our global sales meeting that hits in the first quarter as well. If you look at SG&A as a percent of sales, we expect that to decline through the rest of the year and by the end of the year, our overall SG&A growth will be less than our rate of sales growth.
Donald Morel: We think it continues to help. We just can’t put our hands around the magnitude. You know, clearly we got a little bit of safety ordering going on in some of the high-value categories because of lead time. But it is difficult to quantify in total of that inventory building in any given quarter.
Donald Morel: Yes, it is pretty much status quo. We are just trying to point out the fact that it is really difficult to predict the timing of some of these things. They are lumpy because once we deliver our end of the equation, it is fully up to the customer in terms of the timing of launch, the timing of trials et cetera.
Donald Morel: Thank you very much everyone. We’re off to a good start, and we expect to keep quarter two in line with our quarter one based on our backlog, and look forward to updating you on our Q2 call in early August. Thank you.
William Federici: I think if you extract the impact of the build in Q1 of 2012, the revenue increase would actually look more favorable this quarter. 
William Federici: It is different. It gets integrated into this micro system. But we realized very little margin out of that because it is actually done by our (inaudible) partners.
William Federici: I think, Ross, I mentioned the European business was up 10.3% excluding exchange. That had some of that inventory build due to a very long lead time situation over in Europe. So, you know, exact quantification, as you know, is very, very difficult for us, but there is some of that in there.
